Key Insights

Highlights

Success Rate

97% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.8%

1 terminated out of 125 trials

Success Rate

97.4%

+10.8% vs benchmark

Late-Stage Pipeline

16%

20 trials in Phase 3/4

Results Transparency

16%

6 of 38 completed with results

Key Signals

6 with results97% success

Data Visualizations

Phase Distribution

84Total
Not Applicable (46)
Early P 1 (1)
P 1 (6)
P 2 (11)
P 3 (6)
P 4 (14)

Trial Status

Completed38
Recruiting33
Unknown19
Active Not Recruiting17
Not Yet Recruiting14
Withdrawn2

Trial Success Rate

97.4%

Benchmark: 86.6%

Based on 38 completed trials

Clinical Trials (125)

Showing 20 of 20 trials
NCT07850128Recruiting

Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection

NCT05672927Phase 4Recruiting

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

NCT04255849Phase 3Active Not Recruiting

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

NCT04953130Phase 4RecruitingPrimary

Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

NCT07624123Not ApplicableNot Yet Recruiting

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women Living With HIV

NCT07545746Phase 2Not Yet Recruiting

Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya

NCT07336134Not ApplicableRecruiting

PopSci CHW4CervixHealth

NCT07453459Not ApplicableRecruiting

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

NCT07281599Not ApplicableRecruitingPrimary

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

NCT07697196Not ApplicableNot Yet RecruitingPrimary

Effect of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on HPV DNA Integration

NCT06302725Not ApplicableCompletedPrimary

Vaginal Self-sampling for Detecting High-risk Human Papillomavirus Cervical Infection in Patients With Immune-mediated Inflammatory Diseases

NCT06210854Phase 2RecruitingPrimary

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

NCT06291311RecruitingPrimary

Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants

NCT07202936Active Not Recruiting

Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe

NCT06002126Not ApplicableActive Not Recruiting

Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries

NCT07281677Phase 4Active Not RecruitingPrimary

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

NCT07428330Not ApplicableRecruiting

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

NCT05935644Not ApplicableSuspended

ORCHID: An Online Intervention for Persons With HIV (Miami)

NCT06162676Not ApplicableCompletedPrimary

Game-Based Intervention to Promote HPV Vaccination

NCT06959563Early Phase 1Active Not RecruitingPrimary

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

Scroll to load more

Research Network

Activity Timeline